☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
P-III
Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan
October 4, 2024
BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)
October 4, 2024
UroGen Reports the First Patient Dosing with UGN-103 in P-III (UTOPIA) Study to Treat Low-Grade Intermediate-Risk Non-Muscle Invas...
October 3, 2024
AstraZeneca Reports the US FDA’s sNDA Acceptance of Calquence with Priority Review for Mantle Cell Lymphoma
October 3, 2024
Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and N...
October 1, 2024
AstraZeneca and Daiichi Sankyo Report the US FDA’s sBLA Acceptance of Enhertu with Priority Review to Treat HR+/HER2-low Metastati...
October 1, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.